Fingerprint
Dive into the research topics where Avraham Karasik is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Erratum: Correction to: Glucagon‑like peptide‑1 analogs activate AMP kinase leading to reversal of the Warburg metabolic switch in breast cancer cells (Medical oncology (Northwood, London, England) (2024) 41 6 PII: 177 DOI: 10.1007/s12032-024-02390-w.)
Ligumsky, H., Amir, S., Arbel Rubinstein, T., Guion, K., Scherf, T., Karasik, A., Wolf, I. & Rubinek, T., 27 Mar 2026, In: Medical Oncology. 43, 5Research output: Contribution to journal › Comment/debate
Open Access -
Drug adherence, glycemic control, and weight reduction with subcutaneous semaglutide in real-world management of type 2 diabetes
Melzer Cohen, C., Mosenzon, O., Aharonovich, A., Karasik, A. & Schechter, M., Apr 2025, In: Diabetes Research and Clinical Practice. 222, 112086.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
Glucagon-like peptide-1 analogs activate AMP kinase leading to reversal of the Warburg metabolic switch in breast cancer cells
Ligumsky, H., Amir, S., Arbel Rubinstein, T., Guion, K., Scherf, T., Karasik, A., Wolf, I. & Rubinek, T., Jun 2024, In: Medical Oncology. 41, 6, 138.Research output: Contribution to journal › Article › peer-review
9 Scopus citations -
Projecting the clinical burden of chronic kidney disease at the patient level (Inside CKD): a microsimulation modelling study
Chertow, G. M., Correa-Rotter, R., Eckardt, K. U., Kanda, E., Karasik, A., Li, G., Christiansen, C. F., Stafylas, P., Holt, S. G., Hagen, E. C., Garcia Sanchez, J. J., Barone, S., Cabrera, C., Nolan, S., Coker, T., Webber, L. & Retat, L., Jun 2024, In: EClinicalMedicine. 72, 102614.Research output: Contribution to journal › Article › peer-review
Open Access30 Scopus citations -
Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study
EMPRISE Europe and Asia Study Group, Mar 2023, In: Diabetes and Metabolism. 49, 2, 101418.Research output: Contribution to journal › Article › peer-review
Open Access23 Scopus citations